bioMérieux's Stock Plummets Over 40% in a Year and Tests its 20-Day Moving Average
In a declining Parisian market, heavily influenced by tensions in the Middle East, bioMérieux's stock falls during the session. The Lyon-based company is facing a lowered price target from a major American brokerage, adding to an already significantly deteriorated stock trajectory over the past twelve months.
BofA Lowers Price Target to €80 While Maintaining a Hold Rating
Yesterday, BofA Securities reduced its price target on bioMérieux to €80 from €85 previously. The American firm maintains its neutral stance on the stock. At €69.00, the new target offers a theoretical potential of nearly 16%, but the adjustment reflects a downward revision of the expected valuation by the analysts. The market context is not helping: the CAC 40 is down nearly 2% and the SBF 120 is declining in similar proportions, while the VIX spikes over 11% amid military escalation between the United States and Iran.
The Stock Revisits its 20-Day Moving Average at €68.92 After a Year-Long Decline of Over 42%
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At €69.00, the stock is precisely at its 20-day moving average (€68.92), which now plays a pivotal role after a rebound that began in early July. The stock remains below its 50-day moving average at €70.80 (a gap of -2.54%) and far below its 200-day moving average at €94.55, with a gap of -27% that illustrates the depth of the decline since last year. The RSI at 53 remains in a neutral zone, without a clear directional signal. The loss stands at 5.3% over a month and 42.1% over a year, while the weekly performance remains almost flat. The support at €66.60 is the next numerical threshold to watch if the 20-day moving average were to give way.
SectorSanté · Vaccins et laboratoires de recherche›Équipements Médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
